SEC Form SC 13D/A filed by Spero Therapeutics Inc. (Amendment)

$SPRO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $SPRO alert in real time by email
SC 13D/A 1 gsk_sc13da-110822.htm SCHEDULE 13D/A
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS
THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)*

SPERO THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, Par Value $0.001

(Title of Class of Securities)

84833T 10 3

(CUSIP Number)

Victoria A. Whyte

GSK plc

980 Great West Road

Brentford, Middlesex TW8 9GS

England

Telephone: +44 (0)208 047 5000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

November 7, 2022

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

 

 

 

 

 

 

CUSIP No. 84833T 10 3Page 2 of 7

 

         
1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

GSK plc
   
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ☐
(b)    ☐
   
3.   SEC USE ONLY
 
   
4.   SOURCE OF FUNDS (see instructions)
 
WC
   
5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)    X    
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
England and Wales
   

 

         
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   7.   SOLE VOTING POWER
 
9,190,606
  8.   SHARED VOTING POWER
 
-0-
  9.   SOLE DISPOSITIVE POWER
 
9,190,606
  10.   SHARED DISPOSITIVE POWER
 
-0-

 

       
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,190,606 shares of Common Stock (1)
   
12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)  ☐
   
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

19.99% of the shares of Common Stock (2)
   
14.   TYPE OF REPORTING PERSON (see instructions)

CO
   

 

Footnotes:        

(1)         Common Stock are held of record by GSK Equity Investments, Limited, formerly S.R. One, Limited (“GSK EI”), and Glaxo Group Limited (“GGL”), each of which is an indirect, wholly-owned subsidiary of the Reporting Person.

(2)          The percentage herein is based on 45,972,702 shares of the Issuer’s Common Stock (as defined below), consisting of 38,522,702 shares of Common Stock outstanding as of September 21, 2022, as represented by the Issuer in the Share Purchase Agreement (as defined below), plus 7,450,000 shares of Common Stock newly issued to GGL on November 7, 2022.

 

CUSIP No. 84833T 10 3Page 3 of 7

 

 

Item 1.  Security and Issuer.

 

This Amendment No. 7 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on November 16, 2017 and amended on July 17, 2018, September 19, 2018, February 14, 2020, June 4, 2020, December 7, 2020, and September 16, 2021 (the “Schedule 13D”) with respect to the shares of common stock, par value $0.001 per share (the “Common Stock”), of Spero Therapeutics, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139.

 

Item 2. Identity and Background.

 

The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 in its entirety and replacing it with Schedule 1 attached.

 

Item 3. Source or Amount of Funds or Other Consideration.

 

The response set forth in Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following:

 

GSK plc, through its wholly-owned indirect subsidiary GGL, acquired from the Issuer 7,450,000 shares of Common Stock on November 7, 2022 through transactions contemplated by the SPA (as defined below), at a purchase price of approximately $1.20805 per share, for an aggregate purchase price of $9.0 million. The consideration was obtained from the working capital paid by GGL.

 

Item 4.  Purpose of Transaction.

 

Item 4 is amended by adding the following:

 

License Agreement with GSK

 

On September 21, 2022, the Issuer entered into a license agreement (the “License Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GIP”). Pursuant to the terms of the License Agreement, the Issuer granted GIP an exclusive royalty-bearing license, with the right to grant sublicenses, under the Issuer’s intellectual property and regulatory documents and a sublicense under certain intellectual property of Meiji Seika Pharma Co., Ltd. (“Meiji”) and Meiji’s regulatory documents to develop, manufacture and commercialize tebipenem pivoxil and tebipenem HBr and products that contain tebipenem pivoxil and tebipenem HBr (the “GSK Licensed Products”) in all territories, except certain Asian countries previously licensed to Meiji (Japan, Bangladesh, Brunei, Cambodia, China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam, or the “Meiji Territory”) (the “GSK Territory”). If the Issuer’s license with Meiji is terminated, or if Meiji forfeits or loses its rights to develop, manufacture and commercialize tebipenem HBr and products that contain tebipenem HBr in any countries in the Meiji Territory, then GIP will have an exclusive first right to negotiate with Spero to add any such countries to the GSK Territory.

 

 

Share Purchase Agreement

 

On November 7, 2022 (the "Closing Date"), Glaxo Group Limited ("GGL"), an indirect,wholly-owned subsidiary of the Reporting Person, purchased 7,450,000 shares (the "Shares") of the Issuer's Common Stock, at a purchase price of approximately $1.20805 per share, for an aggregate purchase price of $9.0 million, pursuant to a stock purchase agreement dated as of September 21, 2022 (the "Effective Date") between the Issuer and GGL (the "SPA").

 

The SPA contains the following standstill, lock-up and registration rights provisions:

 

·Standstill. Prior to the one-year anniversary of the Effective Date, GGL and its affiliates shall not, without the Issuer’s prior written consent, among other things, directly or indirectly acquire additional shares of Common Stock, seek or propose a tender or exchange offer, merger or other business combination involving the Issuer, seek, propose or cause any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to the Issuer, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Issuer, in each case, subject to customary exceptions.

 

CUSIP No. 84833T 10 3Page 4 of 7

 

 

·Lock-Up. From and including the Effective Date until the date that is twenty-four (24) months from and after the Effective Date (the “Lock-up Period”), and subject to customary exceptions, neither GGL nor its affiliates shall sell or otherwise dispose of the Shares, or any other shares of Common Stock owned beneficially by GGL and/or its affiliates (collectively, the “Locked-Up Shares”), provided, however, such Lock-up Period shall expire from and after eighteen (18) months after the Effective Date, with respect to 50% of the Locked-Up-Shares.



·Registration Rights. If, following the fifteen (15) month anniversary of the Closing Date, GGL or any of its affiliates proposes to publicly resell any or all of the shares of Common Stock then held by them (the “Registrable Securities”) (subject to the lock-up periods described above) pursuant to Rule 144 (“Rule 144”) under the Securities Act of 1933, as amended (the “Securities Act”), and GGL or any of its affiliates in good faith believes they will be unable to sell all of their respective shares of Common Stock proposed to be sold by them pursuant to Rule 144 without volume or manner-of-sale restrictions, then GGL shall have the right to require the Issuer to file as promptly as practicable a secondary only registration statement on Form S-3 (or any successor form to Form S-3) promulgated under the Securities Act (the “Registration Statement”), registering the resale of such shares of Common Stock. The Issuer shall use commercially reasonable efforts to cause the Registration Statement to become effective as promptly as practicable and to cause the Registration Statement to remain effective until the earlier of (i) the date on which GGL and its affiliates have disposed of all of the Registrable Securities, (ii) such time as Rule 144 is available for the disposition of all Registrable Securities without volume or manner-of-sale restrictions and (iii) the eighth (8th) anniversary of the effectiveness date of the Registration Statement. The Issuer shall bear all expenses incurred in connection with the performance of the foregoing obligations and such rights shall apply to any shares in the capital of the Issuer issued or issuable with respect to the Registrable Securities as a result of any stock split, stock dividend, recapitalization, exchange or similar event. For the avoidance of doubt, GGL and its affiliates shall remain subject to the lock-up restrictions described above, even if the Registration Statement becomes effective before the eighteen (18) month anniversary of the Effective Date.

 

The foregoing is only a summary of the material terms of the License Agreement and SPA and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by the attached exhibits.

 

 

Item 5.  Interest in Securities of the Issuer.

 

The response set forth in Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

 

(a), (b) The information contained in rows 7, 8, 9, 10, 11, and 13 on each of the cover pages of this Statement is incorporated by reference in its entirety into this Item 5.

 

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

Item 6 is amended by adding the following:

 

Except as disclosed in Item 4 of this Statement, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between GSK plc or any of its subsidiaries and any other person with respect to any securities of the Company.

 

 

 

Item 7. Material to Be Filed as Exhibits.

 

Exhibit   Name
3   Executive License Agreement, dated as of September 21, 2022, entered into by and between the Issuer and GIP, incorporated by reference to Exhibit 10.3 to the Issuer's Form 10-Q (File No. 001-38266) furnished to the Securities and Exchange Commission on November 14, 2022.
4   Share Purchase Agreement, dated as of September 21, 2022, entered into by and between the Issuer and GGL, incorporated by reference to Exhibit 10.4 to the Issuer's Form 10-Q (File No. 001-38266) furnished to the Securities and Exchange Commission on November 14, 2022.

 

 

CUSIP No. 84833T 10 3Page 5 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 14, 2022

  GSK PLC
  By: /s/ Victoria A. Whyte
  Name: Victoria A. Whyte
  Title:  Authorized Signatory

 

 

 

 

 

 

 

 

CUSIP No. 84833T 10 3Page 6 of 7

 

Schedule 1

 

Name

Business Address

Principal Occupation or Employment

Citizenship

       
Board of Directors      
Emma Walmsley 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Executive Director and Chief Executive Officer British
Charles Bancroft 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Company Director US

Elizabeth McKee

Anderson

980 Great West Road
Brentford
Middlesex TW8 9GS, England
Company Director US
Dr. Hal Barron

269 E. Grand Avenue,

South San Francisco,

CA 94080

Company Director US
Dr. Anne Beal 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Company Director US
Dr. Harry (Hal) Dietz 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Company Director US
Dr. Jesse Goodman 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Company Director US
Iain Mackay 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Executive Director & Chief Financial Officer British
Urs Rohner 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Company Director Swiss
Dr. Vishal Sikka 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Company Director US
Sir Jonathan Symonds 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Chairman and Company Director British
GSK Leadership Team      
Emma Walmsley 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Executive Director and Chief Executive Officer British
Roger Connor 980 Great West Road
Brentford
Middlesex TW8 9GS, England
President, Vaccines & Global Health Irish
Diana Conrad 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Chief People Officer Canadian
James Ford 980 Great West Road
Brentford
Middlesex TW8 9GS, England
SVP and Group General Counsel, Legal and Compliance British & US
Sally Jackson 980 Great West Road
Brentford
Middlesex TW8 9GS, England
SVP, Global Communications and CEO Office British
Iain Mackay 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Executive Director & Chief Financial Officer British
Luke Miels 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Chief Commercial Officer Australian

 

CUSIP No. 84833T 10 3Page 7 of 7

 

Shobana Ramakrishnan 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Chief Digital & Technology Officer US
David Redfern 980 Great West Road
Brentford
Middlesex TW8 9GS, England
President, Corporate Development British
Regis Simard 980 Great West Road
Brentford
Middlesex TW8 9GS, England
President, Global Supply Chain French & British
Philip Thomson 980 Great West Road
Brentford
Middlesex TW8 9GS, England
President, Global Affairs British
Deborah Waterhouse 980 Great West Road
Brentford
Middlesex TW8 9GS, England
CEO, ViiV Healthcare British
Dr. Tony Wood 980 Great West Road
Brentford
Middlesex TW8 9GS, England
Chief Scientific Officer British

 

 

 

 

 

 

Get the next $SPRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SPRO

DatePrice TargetRatingAnalyst
12/20/2024$5.00Outperform → In-line
Evercore ISI
9/23/2022$2.00 → $8.00In-line → Outperform
Evercore ISI
10/1/2021Outperform → Perform
Oppenheimer
More analyst ratings

$SPRO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

    CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceCompany presentation:Tuesday March 4, 2025 Time:3:10 PM ET    To request a meeting or for

    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceCompany presentation: Wednesday March 5, 2025Time: 3:10 PM ET    To request a meeting or

    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SPRO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SPRO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SPRO
SEC Filings

See more

$SPRO
Leadership Updates

Live Leadership Updates

See more
  • Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

    CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Ms. Rajavelu will succeed Stephen DiPalma, who has served as the company's Interim CFO since August 1, 2023. "We are thrilled to welcome Esther to the executive leadership team as our new CFO and CBO. Esther brings a proven track record in corporate finance, from both indus

    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

    BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

    $PTCT
    $SPRO
    $TCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

    Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023 Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat "Sath" Shukla, Spero's current Chief Financial Officer and Treas

    $GSK
    $PFE
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SPRO
Financials

Live finance-specific insights

See more
  • Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

    CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

    CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments fo

    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

    Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024New SPR720 in-vitro resistance data to be presented at IDWeek 2024 conference in OctoberCompany announces departure of Chief Medical Officer Kamal Hamed, MD, MPH, MBA; Appoints Board member and Chair of Development Committee John C. Pottage, Jr., M.D., as Special Advisor to oversee medical function; search ongoing for a new CMOCash balance of $63.5 million as of June 30, 2024; reiterate expected cash runway into late 2025Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Aug. 05, 2024 (GLO

    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SPRO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more